Biota Announces Inavir® Royalty for March 2011 Quarter
May 12 2011 - 8:00AM
Business Wire
Biota Holdings Limited (ASX:BTA) advises that it has received
written notification from Daiichi Sankyo that sales of Inavir® were
JPY 3.9 billion and royalties to Biota were AUD 1.6 million in the
three months to 31 March 2011.
Royalties are after allowance for specified selling costs and
Japanese withholding tax. Under the agreement with Daiichi Sankyo,
Biota expects to receive these funds by the end of May.
About Inavir®
Inavir® is the first drug of a new class of long acting
neuraminidase inhibitors (LANIs) to address the limitation of the
current products, which require daily or more frequent dosing. The
new class provides the opportunity to medicate patients on a "one
and done" basis and offers a number of potential benefits. These
include that the patient is more likely to use the product properly
and as intended and also offers a reduced cost of storage and
transport per course, where the product is intended to be
stockpiled. Inavir® is Daiichi Sankyo's registered brand for
laninamivir octanoate, also previously known as CS-8958. Inavir® is
delivered via a Dry Power Inhaler.
About Biota
Biota is a leading anti-infective drug development company based
in Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza. Biota research breakthroughs include a
series of candidate drugs aimed at treatment of respiratory
syncytial virus (RSV) disease and Hepatitis C (HCV) virus
infections. Biota has clinical trials underway with its lead
compound for human rhinovirus (HRV) infection in patients with
compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza anti-virals, of which the lead product
lnavir®, is approved for marketing in Japan.
Relenza™ is a registered trademark of the GlaxoSmithKline group
of companies.
Inavir® is registered to Daiichi Sankyo.
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Jul 2023 to Jul 2024